The following video interview with Dr Eric Jonasch, from the MD Anderson Cancer Center, Houston, Texas, describes the current role of mTOR inhibitors for the treatment of metastatic renal cell carcinoma (mRCC). Watch the video interview on Practice Update here
Results from the phase 3 CARMENA study, published in the journal JAMA Oncology, found that pretreatment of renal cell carcinoma (RCC) patients with sunitinib followed by deferred cytoreductive nephrectomy did not improve 28-week progression-free survival rates compared with immediate nephrectomy followed by sunitinib in these patients. However, patients who received sunitinib followed by deferred cytoreductive […]
In an interview with OncLive, Dr Toni Choueiri from Harvard Medical School, Dana-Farber Cancer Institute in America, discusses recent progress in renal cell carcinoma (RCC) and future research in this area. Dr Choueiri talks about the breakthroughs in the treatment of patients with RCC over the last decade, such as checkpoint inhibitors, targeted agents, and combination […]
A recent study published in the Lancet Oncology has identified that the mutation status of three genes – BAP1, PBRM1, and TP53 – had independent prognostic value for patients with advanced or metastatic renal cell carcinoma (RCC) about to start treatment with first-line tyrosine kinase inhibitors (TKIs). The mutation status of these three genes is useful for helping to determine […]
New research from an American group based at Roswell Park Comprehensive Cancer Center, New York shows that if cancer patients exercise regularly both before and after their diagnosis, they are significantly more likely to survive cancer than those who are sedentary. This adds to the growing evidence that physical activity is important for the prevention […]
A new report by the Institute of Cancer Research (ICR) has found that patients are waiting longer for new cancer drugs to be approved for use with the NHS because of delays in clinical trials and regulatory approval for use. The report found that the average time taken from the start of phase I clinical […]
Cally Palmer, NHS England’s national cancer director announced at the Britain Against Cancer conference yesterday that the first patient in England is to begin state of the art proton beam therapy for cancer at The Christie Hospital in Manchester this month, marking a major milestone for NHS care. The second proton beam therapy machine is […]
This multicentre analysis of axitinib versus sunitinib used as first-line treatment for metastatic renal cell carcinoma (RCC) in 169 patients shows that compared with sunitinib, axitinib significantly prolonged cancer-specific survival and overall survival. Axitinib also had a safer adverse event profile compared to sunitinib as a first-line therapy for previously untreated metastatic RCC. Read the […]
Three talented surgeons have performed what is believed to be the first combined renal and bowel cancer surgery in the North West using robotic surgery assisted by the Da Vinci robot. The surgery was performed at the Royal Blackburn Teaching Hospital, East Lancashire Hospitals NHS Trust. The patient was given pioneering surgery involving a partial […]
A recent analysis of data from the phase 3 Checkmate-214 clinical trial showed that first-line treatment with the nivolumab/ipilimumab combination significantly delayed the need for subsequent treatment in patients with advanced or metastatic renal cell carcinoma (RCC), compared with standard treatment with sunitinib. This benefit was also seen in patients who had stopped treatment, and […]
Copyright 2017 Kidney Cancer Support Network- Douglass Digital | Cambridge Web Design
